GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Other Cash Receipts from Operating Activities
中文

Prescient Therapeutics (ASX:PTX) Other Cash Receipts from Operating Activities : A$2.38 Mil (TTM As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Other Cash Receipts from Operating Activities?

Prescient Therapeutics's Other Cash Receipts from Operating Activities for the six months ended in Dec. 2023 was A$2.37 Mil.

Prescient Therapeutics's Other Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.38 Mil.


Prescient Therapeutics Other Cash Receipts from Operating Activities Historical Data

The historical data trend for Prescient Therapeutics's Other Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Other Cash Receipts from Operating Activities Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Cash Receipts from Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 1.63 1.03 1.30 1.64

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Cash Receipts from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 0.11 1.69 0.01 2.37

Prescient Therapeutics Other Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Other Cash Receipts from Operating Activities represents cash flow received from other operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Other Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prescient Therapeutics Other Cash Receipts from Operating Activities Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Other Cash Receipts from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (ASX:PTX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Other Cash Receipts from Operating Activities
Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines